Core Viewpoint - Phibro Animal Health reported strong financial performance in the second quarter, with significant revenue and adjusted net income growth, leading to raised guidance for future financial metrics [2][5]. Financial Performance - The company achieved 21% revenue growth and 60% growth in adjusted net income, generating $94 million in revenue for the quarter [2][5]. - Following a robust first half, the company raised its guidance for revenue, EBITDA, and adjusted net income, reflecting positive investor feedback [1][5]. Business Segments - Continued growth was noted in vaccines (13% growth) and nutritional specialties (9% growth) for the quarter [1]. - The legacy Medicated Feed Additives (MFA) business experienced a 5% decline due to order timing but would have grown approximately 3% when normalized [1]. Strategic Focus - Management is prioritizing higher-margin growth in vaccines and nutritional specialties, aiming for mid-to-high single-digit growth and margin expansion [3][7]. - The integration of the Zoetis MFA portfolio is progressing well, with expectations for MFA growth to be flat to low-mid single digits long-term, targeting outperformance post-fiscal 2027 [4][6]. Market Dynamics - Strong end-market demand for animal-based protein and effective execution across segments contributed to recent performance [9]. - Consumer demand for meat, eggs, and dairy remains robust despite inflation, with demographic trends favoring high-quality protein consumption [10]. Competitive Positioning - Phibro is positioned as a strong competitor in the MFA market, likely ranking second globally, with key competitors including Elanco and Huvepharma [14]. - The company is also focusing on pricing adjustments during the integration of the Zoetis MFA portfolio to enhance margins [15]. Companion Animal Business - The company has launched a new product, Restoris, in the companion animal segment, which is expected to grow significantly over time [16]. - Management plans to reinvest profits from this segment while maintaining fiscal conservatism [16]. Leadership Transition - Dani Bendheim is set to become CEO later this year, with a focus on continuity in strategy and operations [3][17]. - The broader management team will remain in place, ensuring stability during the transition [18].

Summary of Phibro Animal Health Conference Call Company Overview - **Company**: Phibro Animal Health (NasdaqGM: PAHC) - **Date**: February 26, 2026 - **Key Speakers**: Dani Bendheim (Chief Strategy Officer and incoming CEO), Glenn David (CFO), Larry Miller (COO) Key Points Financial Performance - **Fiscal 2Q Results**: - Revenue growth of **21%** year-over-year - Adjusted net income growth of **60%** - Total revenue for the quarter was **$94 million** [5][6] - **Legacy MFA Business**: - Experienced a **5% decline** due to timing of orders from a major customer, but normalized growth was around **3%** [5][6] - **Vaccine Portfolio**: - Grew by **13%** - **Nutritional Specialty**: - Grew by **9%** - **Guidance Update**: - Confidence to raise guidance for revenue, EBITDA, and adjusted net income for the year [6][7] Strategic Developments - **Zoetis Acquisition**: - Integration of the Zoetis Medicated Feed Additive (MFA) portfolio is progressing well, expected to enhance overall business [11][12] - Anticipated growth in MFA portfolio to be flat to low mid-single digits in the long term, with vaccines and nutritional specialties expected to grow mid to high single digits [12][13] - **Market Dynamics**: - Strong demand for animal-based protein consumption is driving growth in the livestock market [20][24] - The company is focusing on building relationships with customers and addressing new disease challenges [21][22] Competitive Landscape - **Positioning**: - Phibro is positioned as a strong competitor in the MFA market, likely the **number two globally** [47][48] - Competes with Elanco and Huvepharma in the MFA space, while facing more competition in vaccines from Zoetis, Merck, and others [48][49] - **Market Share**: - Growth in sales suggests potential market share expansion, particularly through innovation and addressing emerging diseases [52] Pricing Strategy - **Pricing Power**: - The company has identified opportunities for price adjustments, particularly in acquired products, without significant volume drops [54][56] - Future price increases are expected to be low single-digit as products mature [58] Companion Animal Business - **Growth Potential**: - Companion animal products like Restoris and Regensa are showing strong growth, with plans to reinvest profits into this segment [61][62] - **Long-term Strategy**: - Aiming to establish the companion animal segment as a fourth pillar alongside MFAs, nutritional specialties, and vaccines [63] Margin Expansion - **Drivers of Margin Growth**: - Positive mix dynamics, growth in higher-margin products, and initiatives from the Phibro Forward program are contributing to margin expansion [65][66] - **Future Outlook**: - The company expects to continue driving income growth faster than revenue, with Phibro Forward hitting its peak in fiscal year 2027 [67] Leadership Transition - **CEO Transition**: - Dani Bendheim will take over as CEO, emphasizing continuity in strategy and operations [70][72] Additional Insights - **Cultural Integration**: - The integration of Zoetis employees and culture has been positive, with excitement about the new direction [40][41] - **Customer Reception**: - Positive feedback from customers regarding the expanded product portfolio and support [44][45] This summary encapsulates the key points discussed during the Phibro Animal Health conference call, highlighting financial performance, strategic developments, competitive positioning, pricing strategies, and future outlook.

Financial Performance - Consolidated net sales for Q2 2026 were $373.9 million, reflecting a 21% increase year-over-year [12] - Animal health segment sales grew by 26%, while Mineral Nutrition increased by 9%, and Performance Products declined by 10% [12][14] - Adjusted EBITDA increased by 41% to $82.2 million, driven by the new MFA business and improved gross profit [15][18] - Adjusted net income rose by 60%, and adjusted diluted EPS increased by 58% [14] Business Segment Performance - Animal health segment net sales reached $290 million, a 26% increase, with the new MFA business contributing $94.1 million [14][15] - Nutritional specialties saw a 9% increase in net sales due to higher North American demand for dairy [15] - Vaccine net sales grew by 13%, driven by poultry products in Latin America and higher international demand [15] - Mineral nutrition segment net sales were $68.9 million, a 9% increase, while Performance Products segment sales decreased by 10% to $15 million [15][16] Market Insights - The protein markets are experiencing strong demand, particularly in beef, chicken, pork, turkey, dairy, and eggs [32] - Favorable feed costs are helping maintain margins, with expectations of some shifts in trade due to tariffs and disease outbreaks [32] - The company is well-diversified across livestock species and geographic markets, enhancing its competitive position [33] Company Strategy and Direction - The company is focused on sustainability and profitability, emphasizing better gut health and improved feed conversion [11] - The Phibro Forward strategy aims to drive future growth through R&D and digital capabilities [11][50] - The leadership transition is seen as an opportune moment, with continuity in management and a strong cultural foundation [10] Management Commentary - Management expressed confidence in the company's direction and the strength of its business, citing positive feedback from customers and strong alignment among leadership [7][9] - The integration of the MFA portfolio is yielding positive results, with management noting strong performance and customer partnerships [5][8] Other Important Information - The company raised its full-year guidance for fiscal year 2026, with net sales expected to be between $1.45 billion and $1.5 billion [18] - The gross leverage ratio was 3.1x, and net leverage ratio was 2.8x at the end of the quarter [17] Q&A Session Summary Question: What are the main drivers of gross margins this quarter? - Management highlighted successful pricing strategies, positive product mix, and internal focus on higher-margin products as key drivers [22][23] Question: Can you elaborate on the guidance update and what is performing better than expected? - Management noted strong revenue performance, effective integration of the acquired portfolio, and improved mix as factors contributing to the positive outlook [24][25] Question: What impact did customer timing have on the MFA business? - Management explained that fluctuations in customer inventory levels affected sales, but improvements are expected in the next quarter [28][29] Question: How sustainable is the current demand in livestock markets? - Management expressed confidence in the sustainability of demand due to diversification and favorable feed costs [32][33] Question: Are there share gains from the stronger combined portfolio? - Management confirmed strong performance in poultry and swine segments, indicating share gains due to a more complete product offering [35][41] Question: Update on the Phibro Forward initiative? - Management stated that Phibro Forward continues to be a significant growth driver, with expected contributions accelerating through fiscal year 2026 [48][50]

Financial Performance - Consolidated net sales for Q2 2026 were $373.9 million, reflecting a 21% increase year-over-year [12] - Animal health segment sales grew by 26%, while mineral nutrition increased by 9%, and performance products declined by 10% [12][14] - Adjusted EBITDA increased by 41% to $82.2 million, driven by the new MFA business and improved gross profit [15] - Adjusted net income rose by 60%, and adjusted diluted EPS increased by 58% [14] Business Segment Performance - Animal health segment net sales reached $290 million, a 26% increase, with the new MFA business contributing $94.1 million [14][15] - Nutritional specialties net sales increased by 9% due to higher demand in North America [15] - Vaccine net sales grew by 13%, driven by poultry products in Latin America [15] - Mineral nutrition segment net sales were $68.9 million, a 9% increase, while performance products segment sales decreased by 10% [15][16] Market Insights - The protein markets are experiencing strong demand, particularly in beef, poultry, pork, turkey, dairy, and eggs [32] - Favorable feed costs are helping maintain margins, with expectations of some shifts in trade due to tariffs and disease outbreaks [32] - The company is well-diversified across livestock species and geographic markets, enhancing its competitive position [33] Company Strategy and Direction - The company is focused on sustainability and profitability, emphasizing better gut health and improved feed conversion [11] - The Phibro Forward strategy aims to drive future growth through R&D and digital capabilities [11][50] - The leadership transition is seen as an opportune moment to capitalize on current momentum and operational excellence [10][11] Management Commentary - Management expressed confidence in the company's direction and the strength of its business, citing positive feedback from customers and strong alignment within the leadership team [7][9] - The integration of the MFA portfolio is yielding positive results, with management noting a strong performance in the acquired business [24][40] Other Important Information - The company raised its full-year guidance for fiscal year 2026, with net sales expected to be between $1.45 billion and $1.5 billion [18] - Adjusted EBITDA guidance was increased to a range of $245 million to $255 million, reflecting a growth range of 33%-39% [18] - Cash and cash equivalents were reported at $74.5 million, with a gross leverage ratio of 3.1 times [17] Q&A Session Summary Question: What are the main drivers of the strong gross margins this quarter? - Management highlighted successful pricing strategies, positive product mix, and internal focus on higher-margin products as key drivers [23][24] Question: Can you elaborate on the guidance update and what is performing better than expected? - Management noted strong revenue performance, effective integration of the acquired portfolio, and improved mix as factors contributing to the positive outlook [25] Question: What impact did customer timing have on the MFA business? - Management explained that fluctuations in customer inventory levels affected sales, but improvements are expected in the next quarter [29] Question: How sustainable is the current demand in livestock markets? - Management expressed confidence in the sustainability of demand due to strong consumer interest and favorable feed costs [32] Question: Are you gaining market share with the combined portfolio? - Management confirmed strong performance in poultry and swine segments, indicating share gains due to a more comprehensive product offering [35][40]

Financial Performance - Consolidated net sales for Q2 2026 were $373.9 million, reflecting a 21% increase year-over-year [11] - Animal health segment sales grew by 26%, while mineral nutrition increased by 9%, and performance products declined by 10% [12] - Adjusted EBITDA increased by 41% to $82.2 million, driven by the new MFA business and improved gross profit [13] - Adjusted net income rose by 60%, and adjusted diluted EPS increased by 58% [12] Business Segment Performance - The animal health segment reported net sales of $290 million, a 26% increase, with the new MFA business contributing $94.1 million [12][13] - Nutritional specialties net sales increased by 9% due to higher demand in North America [13] - Vaccine net sales grew by 13%, driven by poultry products in Latin America [13] - Mineral nutrition segment net sales were $68.9 million, a 9% increase, while performance products declined to $15 million, a 10% decrease [13][14] Market Insights - Demand for high-quality proteins remains strong across various livestock sectors, including beef, poultry, and dairy [30][31] - Favorable feed costs are helping maintain margins, with expectations of some shifts in trade due to tariffs and disease outbreaks [30] - The company is well-diversified across livestock species and geographic markets, enhancing its competitive position [31] Company Strategy and Direction - The company is focused on sustainability and profitability, emphasizing better gut health and improved feed conversion [10] - The Phibro Forward strategy aims to drive future growth through R&D and digital capabilities [10][48] - Leadership transition is positioned to occur from a place of momentum and operational excellence [9] Management Commentary - Management expressed confidence in the company's direction and the strength of its business, citing positive feedback from customers and strong performance metrics [6][8] - The integration of the MFA portfolio is seen as a significant contributor to current success [5][12] - Management anticipates continued strong performance and demand for products globally [17] Other Important Information - The company raised its fiscal year 2026 guidance for net sales to a range of $1.45 billion to $1.5 billion, representing a growth range of 12%-16% [16] - Adjusted EBITDA guidance was increased to a range of $245 million to $255 million, reflecting a growth range of 33%-39% [16] - Cash and cash equivalents were reported at $74.5 million, with a gross leverage ratio of 3.1 times [15] Q&A Session Summary Question: What are the main drivers of gross margins this quarter? - Management highlighted strong pricing, positive product mix, and effective internal growth strategies as key drivers of gross margins [20][21] Question: Can you elaborate on the guidance update and what is performing better than expected? - Management noted strong revenue performance, effective integration of the acquired portfolio, and improved mix as factors contributing to the positive outlook [22][23] Question: What impact did customer timing have on the MFA business? - Management explained that customer inventory levels caused fluctuations, with expectations for improvement in the next quarter [27] Question: How sustainable is the current demand in livestock markets? - Management expressed confidence in the sustainability of demand due to strong consumer interest and favorable feed costs [30] Question: Are there share gains from the stronger combined portfolio? - Management confirmed that the company has seen strong performance and share gains in poultry and swine segments due to a more complete product offering [33][40]

Industry Overview - The Zacks Medical - Products industry is facing challenges due to tariffs imposed by the U.S. on trading partners, impacting margins for companies like GE HealthCare, Baxter, and Abbott [1] - Medical device makers are experiencing rising commodity and manufacturing costs post-COVID-19, particularly in consumer-facing areas like Nutrition, leading to price hikes that may constrain volume due to increased price sensitivity among consumers [2] - The industry's profitability is under strain from tariff-related expenses and persistent component shortages, which create inefficiencies and constrain output [7] Trends and Innovations - Industry players are mitigating challenges through product innovation and the adoption of AI and digital services, with the rise of GLP-1 medication acting as a tailwind for certain medical device areas [3] - The market for remote patient monitoring platforms is projected to reach $57 billion by 2030, driving margin expansion and shifting profit pools from hardware to data-driven services [9] - The U.S. market is shifting from inpatient hospital settings to Ambulatory Surgery Centers (ASCs) and home-based monitoring, with the ASC market expected to reach $205 billion by 2030 [10] Company Performance - Boston Scientific (BSX) is positioned for strong growth driven by demand across its diversified product portfolio, with a commitment to over 10% growth over the next three years [29] - ResMed is experiencing strong momentum with 11% top-line growth in Q2 fiscal 2026, driven by rising demand for CPAP therapy and the adoption of GLP-1 drugs [35][36] - Phibro Animal Health Corporation (PAHC) is benefiting from the integration of the Zoetis Medicated Feed Additive portfolio, contributing $80.5 million in sales in Q1 fiscal 2026, and expects favorable net price impacts to improve profitability [42] Financial Outlook - The Zacks Consensus Estimate for BioLife Solutions (BLFS) indicates a 16.4% revenue growth for 2026, with earnings expected to grow by 38.1% [27] - Boston Scientific's revenue for 2026 is estimated at $22.32 billion, projecting an 11.3% growth, with EPS expected to improve by 13.5% [32] - ResMed's revenue for fiscal 2026 is pegged at $5.58 billion, indicating an 8.5% growth, with EPS expected to rise by 15% [39] - PAHC's revenue for fiscal 2026 is estimated at $1.47 billion, projecting a 13.1% growth, with EPS expected to improve by 32.1% [46]

Financial Performance and Key Metrics - Consolidated net sales for Q1 2026 were $363.9 million, a 40% increase year-over-year, driven by a 55% growth in the animal health segment [8][9] - Adjusted EBITDA for Q1 increased by 102% to $31.2 million, with adjusted net income rising by 112% and adjusted diluted EPS increasing by 108% [8][9] - The animal health segment's net sales reached $283.5 million, reflecting a 55% increase, while mineral nutrition grew by 7% and performance products declined by 7% [9][10] Business Line Performance - Medicated feed additives saw an 81% growth, with the new MFA business contributing $80.5 million in sales [5][9] - Nutritional specialties net sales increased by 13%, primarily due to higher demand for microbial and companion animal products [9] - Vaccine sales grew by 25%, driven by poultry products in Latin America and increased international demand [9] Market Data and Key Metrics - Strong demand for animal-based proteins is noted, supported by global population growth and changing consumer preferences towards high-quality proteins [30] - Livestock sector profitability remains positive across various regions, with lower feed costs encouraging investment in animal health products [30][31] Company Strategy and Industry Competition - The company is focused on innovation and execution, with the recent launch of Restoris, a dental gel for dogs, marking a significant step in the companion animal strategy [6][23] - The Phibro-forward initiatives aim to enhance operational discipline and drive sustainable long-term value creation [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for products globally and anticipates continued improvement in business performance [13][14] - The company raised its full-year earnings guidance, reflecting strong performance and disciplined financial management [12][13] Other Important Information - The company generated $34 million in positive free cash flow for the 12 months ending September 30, 2025, with a gross leverage ratio of 3.3 times [11] - A quarterly dividend of $0.12 per share was paid, totaling $4.9 million [12] Q&A Session Summary Question: Sustainability of growth in the MFA business - Management noted strong demand across the MFA portfolio, particularly in poultry, swine, and beef cattle segments, with limited impact on pricing in Q1 [15][16][17] Question: Margin profile for the remainder of the year - Management indicated that Q1 margins were favorable due to product mix, but expected a slight drop in margins as investments in new product launches occur [18][19] Question: Guidance update and revenue range - Management explained that while EBITDA and EPS guidance were raised, revenue guidance remained unchanged due to conservatism and being only one quarter into the fiscal year [21][22] Question: Role in the companion animal market - Management confirmed a focus on unique opportunities in the companion animal space, rather than competing directly with larger players [34][36]